The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search instagram avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

The Food and Drug Administration and GlaxoSmithKline recently sent notice to healthcare professionals and pharmacists about a new black box warning on Dexedrine (dextroamphetamine sulfate). The drug, typically prescribed to treat Attention-Deficit Hyperactivity Disorder and narcolepsy, has been shown to cause sudden death in association with CNS stimulant treatment in children and adolescents with heart problems.

Comments for this article are closed.